Merck has talked up the value of its subcutaneous version of Keytruda, arguing that the investigational therapy will increase access to treatment by untethering patients from infusion centers. Roche ...

The increasingly more popular combination of Padcev and Keytruda has expanded its bladder cancer territory once again. | The ...

Both Opdivo and Keytruda come as liquid solutions. The two drugs are given as an intravenous (IV) infusion, which is an injection into your vein given over a period of time. Infusions for both Opdivo ...

Just a few weeks after President Donald Trump’s December promise that prescription drug prices would plummet "fast and furious," Patricia Brown checked into a California clinic for an infusion of ...

Monotherapy in immunotherapy-ineligible patients improved median PFS to 9.7 vs 6.9 months versus physician’s-choice chemotherapy, with 50% vs 47% objective response rates. Combination therapy in PD-L1 ...

Nov 19 (Reuters) - Merck (MRK.N), opens new tab said on Tuesday a study showed its injectable version of cancer drug Keytruda was not inferior to the currently approved intravenous formulation of its ...

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved KEYTRUDA, Merck’ s anti-PD-1 therapy, for the adjuvant treatment of ...

Dec 2 (Reuters) - U.S. drugmaker Merck & Co (MRK.N), opens new tab hopes to patent a new formulation of its $20 billion cancer immunotherapy Keytruda that can be injected under the skin, allowing it ...